 |
Find a Stock's Home Page |
|
| Small Cap Biotech Analysis |
In short, this is a clinical stage biopharmaceutical company trading under a dollar on a major exchange (AMEX), with multiple catalysts to help its share price move significantly higher in the short term (this quarter).
Goldman Small Cap Research share some interesting insights as they initiate coverage of NewCardio (NWCI:OB) with a Speculative Buy recommendation. In his report, analyst Rob Goldman cites several factors for his $4.00 price target.
There are a number of stocks we've been monitoring since we did both trade and watch-list alerts for our subscribers about them. Now is the time you really want to play close attention to them.
That's the biggest difference between NBS and the vast majority of it's stem cell sector competitors. They're in the money.
ImmuneRegen is a young company, but unlike most newer biotechs of this size and experience in the market, its research seems to be gathering quite a bit of attention from places like the NIH, the National Cancer Institute and many others.
News release by NeoStem (Amex:NBS) is a peek into the metamorphasis we learned would be taking place at the company last week.
Some of these newly reported techniques will take a great deal of laboratory time and research to fully develop, but companies like NeoStem, Inc. (AMEX: NBS) have already been working on the potential application of very small embryonic-like stem cells
Shares of RXI Pharmaceuticals Corp. (RXII) continue to rise, after the company's presentation in San Francisco.
These types of situations often present terrific buying opportunities.
Just after some traders had given up on the company's promise to submit their New Drug Application (NDA) ADVENTRX announced on Monday that they had done just that.
